Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | BCL2 | P10415 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148826 | 0.92 | MDM2 (0.43) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL5147693 | 0.89 | MALT1 (0.41) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL14504716 | 0.89 | MDM2 (0.42) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL5152209 | 0.88 | CA12 (0.41) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL6209746 | 0.88 | MDM2 (0.42) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL5148825 | 0.86 | MALT1 (0.43) | MALT1RPA1PTGS2 | |
| SCHEMBL5148755 | 0.86 | MDM2 (0.40) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL5148750 | 0.86 | MALT1 (0.45) | MALT1MDM2MCL1BCL2CHRNA7 | |
| SCHEMBL5147720 | 0.86 | MALT1 (0.47) | MALT1CHRNA7PTGS2 | |
| SCHEMBL5148807 | 0.86 | BCL2 (0.42) | MALT1MDM2MCL1BCL2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1567503-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050632-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | MALT1 1227/4885MDM2 1492/4885MCL1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.